SE0202430D0 - New Compounds - Google Patents

New Compounds

Info

Publication number
SE0202430D0
SE0202430D0 SE0202430A SE0202430A SE0202430D0 SE 0202430 D0 SE0202430 D0 SE 0202430D0 SE 0202430 A SE0202430 A SE 0202430A SE 0202430 A SE0202430 A SE 0202430A SE 0202430 D0 SE0202430 D0 SE 0202430D0
Authority
SE
Sweden
Prior art keywords
sup
new compounds
methods
diastereoisomers
enantiomers
Prior art date
Application number
SE0202430A
Other languages
English (en)
Swedish (sv)
Inventor
Eifion Phillips
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202430A priority Critical patent/SE0202430D0/xx
Publication of SE0202430D0 publication Critical patent/SE0202430D0/xx
Priority to HK05109453.6A priority patent/HK1077571B/en
Priority to NZ537882A priority patent/NZ537882A/en
Priority to MXPA05001583A priority patent/MXPA05001583A/es
Priority to CA002493920A priority patent/CA2493920A1/en
Priority to EP03788214A priority patent/EP1539765B1/en
Priority to US10/524,484 priority patent/US20050239774A1/en
Priority to DE60325234T priority patent/DE60325234D1/de
Priority to AT03788214T priority patent/ATE417049T1/de
Priority to AU2003248592A priority patent/AU2003248592B2/en
Priority to KR1020057002265A priority patent/KR20060002727A/ko
Priority to CNB038194791A priority patent/CN100343256C/zh
Priority to BR0313234-0A priority patent/BR0313234A/pt
Priority to ES03788214T priority patent/ES2316848T3/es
Priority to JP2004529002A priority patent/JP2006507241A/ja
Priority to PCT/SE2003/001277 priority patent/WO2004016617A1/en
Priority to IL16641605A priority patent/IL166416A0/xx
Priority to ZA200501226A priority patent/ZA200501226B/en
Priority to NO20051259A priority patent/NO20051259L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
SE0202430A 2002-08-14 2002-08-14 New Compounds SE0202430D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0202430A SE0202430D0 (sv) 2002-08-14 2002-08-14 New Compounds
PCT/SE2003/001277 WO2004016617A1 (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
AT03788214T ATE417049T1 (de) 2002-08-14 2003-08-13 Biaryldiazabicycloalkanamide als nicotinische acetylcholinagonisten
KR1020057002265A KR20060002727A (ko) 2002-08-14 2003-08-13 니코틴성 아세틸콜린 아고니스트로서의 비아릴디아자비시클로알칸 아미드
MXPA05001583A MXPA05001583A (es) 2002-08-14 2003-08-13 Biaril diazabicicloalcano amidas como agonistas de acetilcolina nicotinicos.
CA002493920A CA2493920A1 (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
EP03788214A EP1539765B1 (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
US10/524,484 US20050239774A1 (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
DE60325234T DE60325234D1 (de) 2002-08-14 2003-08-13 Biaryldiazabicycloalkanamide als nicotinische acetylcholinagonisten
HK05109453.6A HK1077571B (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
AU2003248592A AU2003248592B2 (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
NZ537882A NZ537882A (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
CNB038194791A CN100343256C (zh) 2002-08-14 2003-08-13 作为烟碱性乙酰胆碱激动剂的双芳基取代的二氮杂双环烷烃酰胺
BR0313234-0A BR0313234A (pt) 2002-08-14 2003-08-13 Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
ES03788214T ES2316848T3 (es) 2002-08-14 2003-08-13 Biaril diazabicicloalcano amidas como agonistas de nicotinicos de la acetilcolina.
JP2004529002A JP2006507241A (ja) 2002-08-14 2003-08-13 ニコチン性アセチルコリン作用剤としてのビアリールジアザビシクロアルカンアミド
IL16641605A IL166416A0 (en) 2002-08-14 2005-01-20 Biaryl diazabicloalkane amides as nicotinic acetylcholine agonists
ZA200501226A ZA200501226B (en) 2002-08-14 2005-02-10 Birayl diazabicycloalkane amides as nicotinic acetylcholine agonists
NO20051259A NO20051259L (no) 2002-08-14 2005-03-11 Biaryl-diazabicykloalkanamider som nikotinacetylcholinagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202430A SE0202430D0 (sv) 2002-08-14 2002-08-14 New Compounds

Publications (1)

Publication Number Publication Date
SE0202430D0 true SE0202430D0 (sv) 2002-08-14

Family

ID=20288725

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202430A SE0202430D0 (sv) 2002-08-14 2002-08-14 New Compounds

Country Status (18)

Country Link
US (1) US20050239774A1 (enExample)
EP (1) EP1539765B1 (enExample)
JP (1) JP2006507241A (enExample)
KR (1) KR20060002727A (enExample)
CN (1) CN100343256C (enExample)
AT (1) ATE417049T1 (enExample)
AU (1) AU2003248592B2 (enExample)
BR (1) BR0313234A (enExample)
CA (1) CA2493920A1 (enExample)
DE (1) DE60325234D1 (enExample)
ES (1) ES2316848T3 (enExample)
IL (1) IL166416A0 (enExample)
MX (1) MXPA05001583A (enExample)
NO (1) NO20051259L (enExample)
NZ (1) NZ537882A (enExample)
SE (1) SE0202430D0 (enExample)
WO (1) WO2004016617A1 (enExample)
ZA (1) ZA200501226B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
JP2006519208A (ja) * 2003-02-27 2006-08-24 ニューロサーチ、アクティーゼルスカブ 新規ジアザビシクロアリール誘導体
PL1697378T3 (pl) 2003-12-22 2008-04-30 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
WO2005061511A1 (en) * 2003-12-22 2005-07-07 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
AU2005210039B2 (en) * 2004-02-04 2010-09-02 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
DE602005024677D1 (de) 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
RU2386633C2 (ru) 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
CA2584836A1 (en) 2004-10-15 2006-04-20 Neurosearch A/S Novel azabicyclic aryl derivatives and their medical use
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−７ニコチン性受容体リガンド並びにその製造及び使用
WO2007093601A1 (en) * 2006-02-14 2007-08-23 Neurosearch A/S 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
MX2008014885A (es) 2006-05-30 2008-12-05 Neurosearch As Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil pirimidinilo y su uso medico.
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CA2703163A1 (en) * 2007-10-22 2009-04-30 Memory Pharmaceuticals Corporation (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease
GB0724251D0 (en) 2007-12-12 2008-02-06 Univ Edinburgh Therapeutic compounds and their use
GB0804685D0 (en) * 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2010146338A1 (en) 2009-06-15 2010-12-23 The University Of Edinburgh Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders
DK2477983T3 (en) 2009-09-16 2015-06-29 Univ Edinburgh (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE
JP2013518897A (ja) * 2010-02-03 2013-05-23 エムイーエイチ アソシエイツ，インコーポレイテッド 選択的および生体活性的等配電子体としての多重置換フルオロメタン
BR112012027640B1 (pt) 2010-04-29 2021-08-03 The University Of Edinburgh Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
EP2593447B1 (de) * 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3281423A (en) * 1964-02-03 1966-10-25 Merck & Co Inc 1, 3-ethanopiperazines and process
US4895943A (en) * 1988-10-25 1990-01-23 Pfizer Inc. Preparation of 1,4-diazabicyclo(3.2.2)nonane
US5679673A (en) * 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
FR2809732B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
FR2809731B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
JP2006519208A (ja) * 2003-02-27 2006-08-24 ニューロサーチ、アクティーゼルスカブ 新規ジアザビシクロアリール誘導体
WO2005061511A1 (en) * 2003-12-22 2005-07-07 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
EP1539765B1 (en) 2008-12-10
MXPA05001583A (es) 2005-04-25
WO2004016617A1 (en) 2004-02-26
DE60325234D1 (de) 2009-01-22
HK1077571A1 (en) 2006-02-17
EP1539765A1 (en) 2005-06-15
AU2003248592A1 (en) 2004-03-03
US20050239774A1 (en) 2005-10-27
IL166416A0 (en) 2006-01-15
ES2316848T3 (es) 2009-04-16
BR0313234A (pt) 2005-06-14
NZ537882A (en) 2008-02-29
CN100343256C (zh) 2007-10-17
NO20051259L (no) 2005-05-12
AU2003248592B2 (en) 2008-04-03
ZA200501226B (en) 2006-07-26
JP2006507241A (ja) 2006-03-02
ATE417049T1 (de) 2008-12-15
CA2493920A1 (en) 2004-02-26
KR20060002727A (ko) 2006-01-09
CN1678615A (zh) 2005-10-05

Similar Documents

Publication Publication Date Title
NO20051259L (no) Biaryl-diazabicykloalkanamider som nikotinacetylcholinagonister
DE60328010D1 (de) Heterocyclische verbindungen
DE60334536D1 (de) Furylverbindungen
ATE477256T1 (de) Thienylverbindungen
NO20073551L (no) Nikotinacetylkolinreseptorligander
NO20084915L (no) Nikotinacetylcholinreseptorligander 101
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
SE0104250D0 (sv) Heterocyclic compounds
NO20054787D0 (no) Indenderivater som farmasotiske midler
SE0203303D0 (sv) Novel Compounds
SE0203070D0 (en) Novel compounds
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
SE0400027D0 (sv) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
MXPA05006957A (es) Nuevos derivados de fosforamida.
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
SE0300103D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
NO20073547L (no) Nikotinacetykolinreseptorligander
SE0301445D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0203301D0 (sv) Novel Compounds
SE0300104D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
MXPA05010428A (es) Derivados de diarilmetilidenpiperidina, preparaciones de los mismos y usos de los mismos.